Kalivir is developing cutting-edge, next-generation viral immunotherapy programs for the treatment of cancer.
Featured Startup in our Pitt Innovates Blog
Learn more about Kalivir in this Pittsburgh Tech Council podcast with CEO, Helena Chaye, Ph.D., J.D. and Chief Scientific Officer, Stephen Thorne, Ph.D.
Featured Startup in our Pitt Innovates Blog
Learn more about Kalivir in this Pittsburgh Tech Council podcast with CEO, Helena Chaye, Ph.D., J.D. and Chief Scientific Officer, Stephen Thorne, Ph.D.
Location: United States
Total raised: $14M
Investors 3
| Date | Name | Website |
| 27.08.2022 | University... | innovation... |
| 06.02.2023 | Company K ... | kpartners.... |
| 20.06.2023 | Premier Pa... | premierpar... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.08.2026 | Series A | $14M | - |
Mentions in press and media 6
| Date | Title | Description |
| 25.08.2026 | KaliVir Secures $14 Million to Advance Oncology Pipeline | KaliVir Immunotherapeutics secured $14M in Series A extension funding. Total Series A capital reached $25M. This bolsters clinical development for VET3-TGI. VET3-TGI is a lead oncolytic immunotherapy. It targets advanced solid tumors. Funds... |
| 20.08.2026 | KaliVir Immunotherapeutics Raises $14 Million Series A Extension, Bringing Total Series A Funding To $25 Million | KaliVir Immunotherapeutics has raised a $14 million extension of its Series A financing to support continued clinical development of VET3-TGI, its lead oncolytic immunotherapy candidate for advanced solid tumors. The financing was led by Co... |
| 19.08.2026 | Flip Raises $25M in New Funding | Flip, a Stuttgart, Germany-based AI-native employee experience platform for frontline workers, raised $25M in new funding. Backers included Notion Capital, HV Capital, L-Bank, and a group of angel and institutional investors. The company in... |
| 19.08.2026 | KaliVir Immunotherapeutics Raises $14M in Series A Extension Funding | KaliVir Immunotherapeutics, a Pittsburgh, PA-based clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs, raised $14M in Series A extension funding. The round was led by Company K Partners with p... |
| 19.08.2026 | Network Bio Raises $50M in Funding | Network Bio, a Boston, MA-based biotechnology company building disease-specific AI models from human biological data, raised $50M in financing. Backers included Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, JSL He... |
| - | KaliVir Immunotherapeutics | “multiple therapies, one virus.KALIVIR is developing cutting edge, next-generation oncolytic viral immunotherapy programs for treatment of cancer. LEARN MORE NEWS AND EVENTSAugust 19, 2026 - KaliVir Immunotherapeutics Announces Closing of $... |